Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patient, Consumer Groups Press For More Oversight Of Device Iterations

This article was originally published in The Gray Sheet

Executive Summary

Patient and consumer groups urged better FDA control over modifications to marketed products and expressed support for agency oversight of laboratory-developed tests at a recent update meeting on device user fee reauthorization.


Related Content

Scope Firms, FDA Faulted In 300-Page Senate Report Seeking Device Reforms
House Diagnostics Reg Reform Draft Proposes Pathways For Relaxed Scrutiny
FDA Shoots For New 510(k) Modification Draft Guidance In 2016
Molecular Pathologists Propose Third-Party Review Of High-Risk Dx In Alternative To FDA LDT Plan